<?xml version="1.0" encoding="UTF-8"?><rss version="2.0" xmlns:content="http://purl.org/rss/1.0/modules/content/"><channel><title>佰傲谷BioValley | wechat-feeds</title><link>http://MzU1NTg4OTM3Mg.favicon.privacyhide.com/favicon.ico</link><description>佰傲谷致力于打造一个垂直于生物制品领域的第三方平台。为生物制药企业提供品牌推广、技术咨询、项目交易、企业合作、人才培养等服务。为生物制药行业从业人员提供沟通交流、会议培训、工作求职、个人展示平台。</description><managingEditor> (hellodword)</managingEditor><pubDate>Fri, 05 Feb 2021 13:52:00 +0800</pubDate><image><url>http://MzU1NTg4OTM3Mg.favicon.privacyhide.com/favicon.ico</url><title>佰傲谷BioValley | wechat-feeds</title><link>http://MzU1NTg4OTM3Mg.favicon.privacyhide.com/favicon.ico</link><width>64</width><height>64</height></image><item><title>罗氏终止若干个2020年临床试验失败的中晚期项目</title><link>https://mp.weixin.qq.com/s/-6Me9d_ctQMWmvEQ5Io8wg</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/qygMQht6xpayZjlLMVVkn5VFDYib7QMia3PF163mhQM9hxOwHksFRQu5NzNZGMWoMh3l0hLy9NicCE6tZTkV1YodQ/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>罗氏(Roche)正在做一些内部清理工作，以结束第四季度的业绩。]]></content:encoded><pubDate>Fri, 05 Feb 2021 12:10:15 +0800</pubDate></item><item><title>恒瑞JAK抑制剂治疗溃疡性结肠炎全球II期临床达到主要终点</title><link>https://mp.weixin.qq.com/s/Zq49VhV6lXyhZ02VKJF7lw</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/qygMQht6xpayZjlLMVVkn5VFDYib7QMia3UqS5QEJdrw1IZN5OSqHBVe8gpbqn9m7jhUXyQxpFrI9O9GeBibGFkOw/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>瞄准患者真正的需求，才能让创新有更多的可能。]]></content:encoded><pubDate>Fri, 05 Feb 2021 12:10:15 +0800</pubDate></item><item><title>如何提升国内药品质量管理，实现国际并轨？FDA、NMPA如是说</title><link>https://mp.weixin.qq.com/s/sbVHoOi5glyez-9xFcF8zA</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/qygMQht6xpayZjlLMVVkn5VFDYib7QMia3uQlibwFoAm050OjFBmFQw0DP8cSTUhl75bdaoLcozJMiasKpEd0dBzIA/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>首发！]]></content:encoded><pubDate>Fri, 05 Feb 2021 12:10:15 +0800</pubDate></item><item><title>海和药物提交科创板上市申请，拟募资31.5亿元</title><link>https://mp.weixin.qq.com/s/0oe3ehgSDZoGA702yJHm0A</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/qygMQht6xpYJvlTDRe08hISahbjxGDoN4g4cp4UkheTEuKdLpH8GGbkib8rTlDW1mZLLIPicvicpzv69Rgq5hAiaTA/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>套用第五套上市标准]]></content:encoded><pubDate>Fri, 05 Feb 2021 12:10:15 +0800</pubDate></item><item><title>安进2020财报：总收入254亿美元！5款药物研发亮红灯</title><link>https://mp.weixin.qq.com/s/4267A7wOrtfsRvwhyCqoGw</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/qygMQht6xpYJvlTDRe08hISahbjxGDoNSNJCcBkk7Yaia1AAm3XiaVmav0vJVVzuKrzgHqAVVhGiblJvQAjW81kZQ/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>生物仿制药的威胁仍然存在]]></content:encoded><pubDate>Thu, 04 Feb 2021 12:01:23 +0800</pubDate></item><item><title>GSK加倍下注mRNA技术，1.8亿美元寻找下一代COVID-19疫苗</title><link>https://mp.weixin.qq.com/s/f30jeq0ZNMRiFxbSkVlGig</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/qygMQht6xpYJvlTDRe08hISahbjxGDoNLXqZxoFcXDsM4VBcaoed5poo95eeQSrhTkyHxGEnATxhljhXqsAytA/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>“无人问津”到“门庭若市”]]></content:encoded><pubDate>Thu, 04 Feb 2021 12:01:23 +0800</pubDate></item><item><title>多地上市成药企潮流，贝达药业港股上市申请获证监会受理</title><link>https://mp.weixin.qq.com/s/iiSdBWg11klpHn-dTFgVfg</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/qygMQht6xpYJvlTDRe08hISahbjxGDoNLS14xdjTs46S5Y029R1hJ63WINgZLhmJT01dFRfDicicDKSeuWhEMHUg/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>佰傲谷快讯]]></content:encoded><pubDate>Thu, 04 Feb 2021 12:01:23 +0800</pubDate></item><item><title>科兴新冠灭活疫苗附条件上市申请获国家药监局受理</title><link>https://mp.weixin.qq.com/s/BhuHJTB9MQy-7vO29miFMQ</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/qygMQht6xpYJvlTDRe08hISahbjxGDoNiaaxXZ5J4kOqVxiaopfibK6Fj4JUicQGBm22ISvW4WVmB9DRfQhZIINtoQ/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>佰傲谷分享]]></content:encoded><pubDate>Thu, 04 Feb 2021 12:01:23 +0800</pubDate></item><item><title>股价被腰斩，Immunovant公司宣布终止抗FcRn抗体临床研究</title><link>https://mp.weixin.qq.com/s/eVRCiFICMklNHaMn3-axQQ</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/qygMQht6xpY6fMGLXiafBiaoYnicYxLQJ8f3iafSvOstEOKAqcf9r47NVWI0EbatiatBNI1s7IVfxlrGbl86nGIk2tQ/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>抗FcRn 抗体：自身免疫性疾病的革命性疗法]]></content:encoded><pubDate>Wed, 03 Feb 2021 12:24:56 +0800</pubDate></item><item><title>信达生物PD-1单抗在华获批NSCLC领域适应症</title><link>https://mp.weixin.qq.com/s/jTTMbmpgneqtpKJuanvpmg</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/qygMQht6xpY6fMGLXiafBiaoYnicYxLQJ8fwVvMBLePtpooCIYKgX6OVh6kibrcKibqQjkSiauic19jBdc8dTzQ62UKBw/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>今日（2021年2月2日），国家药品监督管理局（NMPA）药品批准证明文件通知显示，信达生物的信迪利单抗注射]]></content:encoded><pubDate>Wed, 03 Feb 2021 12:24:56 +0800</pubDate></item><item><title>高瓴26亿入股诺诚健华！誓要集齐中国生物医药“七龙珠”</title><link>https://mp.weixin.qq.com/s/ma07O4niBq7htv7OzV8KlA</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/qygMQht6xpY6fMGLXiafBiaoYnicYxLQJ8fDdVC3nR7cmtJHbrcBz9jb3kI0qOkeJ6PtYiaReZC2qRQqz1pS1QibXGA/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>佰傲谷独家]]></content:encoded><pubDate>Wed, 03 Feb 2021 12:24:56 +0800</pubDate></item><item><title>靶向IL-6疗法的十年</title><link>https://mp.weixin.qq.com/s/xLxIxO3w1JUlyxRHwBmZ2Q</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/qygMQht6xpYKMbTs0aHYE88PiaQIicf8zANrtOyIotqpXRibAOkF0ylVE3VkrDyx35soHwqgftHc77f3cHJVD6hIw/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>十年一剑，IL-6疗法的前世今生。]]></content:encoded><pubDate>Tue, 02 Feb 2021 16:46:42 +0800</pubDate></item><item><title>股价涨幅超7%，君实生物与Coherus达成70亿元合作</title><link>https://mp.weixin.qq.com/s/QAXOSotrG2ecK_sOdv22Ew</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/qygMQht6xpYKMbTs0aHYE88PiaQIicf8zAo6lydQ5TicEVdV69zr0NXzF3lWKNPvQR9HTpuovABewQjHTvKJju3Ig/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>未来，本土Biotech的创新药会有更多的机会出海。]]></content:encoded><pubDate>Tue, 02 Feb 2021 16:46:42 +0800</pubDate></item><item><title>转战新阵地，拓宽适应症：新冠背景下的干扰素市场分析</title><link>https://mp.weixin.qq.com/s/baS2n5hhe7O1-_8VsC_tyw</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/qygMQht6xpZrbic47GiaVGf5ickiaQucTbKKZEXko2E7QwNOhoJ6l8bBhRibAyedESgtUnMWrZ9jicib37OcYbiclbrGcg/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>未来可期]]></content:encoded><pubDate>Mon, 01 Feb 2021 12:41:34 +0800</pubDate></item><item><title>股价大涨19%，康希诺腺病毒载体疫苗成功达到预设的主要安全性及有效性标准</title><link>https://mp.weixin.qq.com/s/5J1xs7qBbbxlp_YY5Yd17w</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/qygMQht6xpaLzbpicxSGBQeMTQk52drmPL9LpDCibztjIF1PEogibkKPs7peiaRFtVLGgclToE8N6Z23NQfGzHJG7w/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>愿早日上市]]></content:encoded><pubDate>Mon, 01 Feb 2021 12:41:34 +0800</pubDate></item><item><title>“总体保护效力66%”，首个单剂接种新冠疫苗III期中期分析公布，来自强生</title><link>https://mp.weixin.qq.com/s/crXEElCR73qWuyTkhylmSg</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/qygMQht6xpaLzbpicxSGBQeMTQk52drmPR63lLd03IIhygxCiaHZBqK2AHGk7FJBJyBh5LPXZBS8LJsNiaXVH2g4g/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>美国72%，拉丁美洲66%，南非57%。]]></content:encoded><pubDate>Mon, 01 Feb 2021 12:41:34 +0800</pubDate></item><item><title>靶点药讯46|纵览全球药物靶点动态</title><link>https://mp.weixin.qq.com/s/-oFIFSOzZvfItaMicvjBjA</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/qygMQht6xpZrbic47GiaVGf5ickiaQucTbKKOEGWKAEgMtSmibLb59K7p2kPqEPHyzH5mPAhvCke1tTPkTMh4nA9OGA/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>德琪医药、百济神州、艾伯维、和黄医药、拜耳......]]></content:encoded><pubDate>Sun, 31 Jan 2021 11:57:56 +0800</pubDate></item><item><title>Nat Immunol:成人和儿童新冠抗体应答不同</title><link>https://mp.weixin.qq.com/s/DaoatrP6Et5MdWgi8LSyVQ</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/qygMQht6xpbxfsZ7CGp8pmKTibv4IDh2Z7sBc2ClqpicHUNmYMRF3UbUcvUDoH2WpjaPqp4VsvQWNcI6I5lia3qCQ/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>]]></content:encoded><pubDate>Sun, 31 Jan 2021 11:57:56 +0800</pubDate></item><item><title>恒瑞申报第四款ADC药物，“魔法子弹”的竞争早已开始</title><link>https://mp.weixin.qq.com/s/bb2fX0WsGLaYPRXJ924Efg</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/qygMQht6xpZ3L9WFriaibyFv30JfrGf7uSey6BTsXQXS87zlN2xabf9r054kzB8jAmpeHLib7ZsZJiaicDXaYnmiaPZg/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>谁能分得大蛋糕？]]></content:encoded><pubDate>Sat, 30 Jan 2021 11:30:57 +0800</pubDate></item><item><title>或将实现“三级跳”，百济神州科创板上市申请获受理</title><link>https://mp.weixin.qq.com/s/6mLasvoDioZsWmbaNZgETw</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/qygMQht6xpZ3L9WFriaibyFv30JfrGf7uSz0nt2EvgJ5DmMNfrvexGAicibuY2wz4ANN31EVJVx4I2MJam79UHZMibg/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>百济神州的三级跳]]></content:encoded><pubDate>Sat, 30 Jan 2021 11:30:57 +0800</pubDate></item></channel></rss>